WordNet

PrepTutorEJDIC

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 移植片対宿主病の予防および治療に使用される免疫抑制剤の概要 overview of immunosuppressive agents used for prevention and treatment of graft versus host disease
2. リウマチ性疾患に用いる免疫抑制剤と従来型の（非生物学的製剤の）疾患修飾性抗リウマチ薬の概要 overview of immunosuppressive and conventional non biologic disease modifying drugs in the rheumatic diseases
3. 成人の腎移植における免疫抑制維持療法 maintenance immunosuppressive therapy in renal transplantation in adults
4. 成人の腎移植における免疫抑制誘導療法 induction immunosuppressive therapy in renal transplantation in adults
5. 免疫抑制療法に関連したB型肝炎ウイルス再活性化 hepatitis b virus reactivation associated with immunosuppressive therapy

Therapeutic options for adult patients with previously treated immune thrombocytopenia - a systematic review and network meta-analysis.

Yang R, Lin L, Yao H, Ji O, Shen Q.
Hematology (Amsterdam, Netherlands). 2019 Dec;24(1)290-299.
The great majority of adult patients with immune thrombocytopenia (ITP) who fail to respond to first-line medication or who relapse following response require additional treatment. Although broad guidelines currently exist for second-line and subsequent therapies, none to date have been prescriptive
PMID 30661482

Differentially expressed plasma proteins of β-thalassemia/hemoglobin E patients in response to curcuminoids/vitamin E antioxidant cocktails.

Panachan J, Chokchaichamnankit D, Weeraphan C, Srisomsap C, Masaratana P, Hatairaktham S, Panichkul N, Svasti J, Kalpravidh RW.
Hematology (Amsterdam, Netherlands). 2019 Dec;24(1)300-307.
Iron overload and oxidative stress are the major causes of serious complications and mortality in thalassemic patients. Our previous work supports the synergistic effects of antioxidant cocktails (curcuminoids or vitamin E, N-acetylcysteine, and deferiprone) in treatment of β-thalassemia/Hb E patie
PMID 30661467

Plasma fibrinogen level as possible prognostic biomarker in diffuse large B-cell lymphoma.

Shehata AMF, Aldesoky AI, Gohar SF.
Hematology (Amsterdam, Netherlands). 2019 Dec;24(1)103-107.
Although many studies have assessed numerous molecular and immunohistochemical prognostic markers for diffuse large Bcell lymphoma (DLBCL), there is always a need for simple widely available markers. This study was planned to illustrate the clinical significance of baseline plasma fibrinogen levels
PMID 30198830

英: antirheumatic drug
同: 疾患修飾性抗リウマチ薬 disease-modifying antirheumatic drug DMARD、遅効性抗リウマチ薬 slow-acting antirheumatic drug SAARD
関

遅効性：一般的にこれらの薬剤は効果が出るまでに数ヶ月要する(別名：SAARDs, slow-acting antirheumatic drugs, 遅効性抗リウマチ薬)。

免疫抑制薬は、抗リウマチ薬が奏功しない、あるいは疾患の活動性が高いときに切り札的に用いられるが、これを抗リウマチ薬にふくめるかどうかは謎。(REU.66では抗リウマチ薬に含めていない)

Disease-modifying antirheumatic drugs (DMARDs) is a category of otherwise unrelated drugs defined by their use in rheumatoid arthritis to slow down disease progression. The term is often used in contrast to non-steroidal anti-inflammatory drug, which refers to agents that treat the inflammation but not the underlying cause.
The term "antirheumatic" can be used in similar contexts, but without making a claim about an effect on the course.

抗リウマチ薬はRAの進行を抑えるかどうかは問わない。抗リウマチ薬の下位概念としてDMARDがある(NSAIDsも含まれると考えて良いだろう)。DMARDはNSAIDsを待避させた概念か。